Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol

Autor: Parabiaghi, A, Tettamanti, M, D'Avanzo, B, Barbato, A, Aguglia, Eugenio, Bufalino, C, Cannavo', D, Gandolfo, L, Bassi, M, Erlicher, A, Agnetti, G, Breviario, G, Casacchia, M, Pollce, R, Pomero, P, Colotto, A, Manfrinati, S, Cattaneo, Ci, Corrivetti, G, Pinto, G, Ferranini, L, Marcenaro, M, Vaggi, M, Ghio, L, Natta, W, Ferrato, F, Francomano, A, La Placha, M, Mastroeni, A, Rigamonti, D, Groppi, C, Mauri, Mc, De Gaspari IF, Percudanim, Picci, R, Comino, L, Paschetta, E, Pioli, R, Bignotti, S, Smerieri, G, Ghinaglia, Visani, E, Lucattini, A, Caverzasi, E, Colombo, R, Cervetti, A, D'Aloise, A, Parise, Vf, Florio, V, Hadjichristos, A, D'Avamzo, B, Buratti, G, Buratti, L, De Micheli, A, Furlato, K, D'Onofrio, S, Mariannantoni, I, Rapisarda, F, Riccardi, F, Ruberto, A, Ruggirello, I, Santini, I, Trivelli, F, Ullo, A.

Publikováno v: Acta psychiatrica Scandinavica. 133(1)

Objective To determine whether the prescription of aripiprazole, compared with olanzapine and haloperidol, was associated with a lower frequency of metabolic syndrome (MS) and treatment discontinuation at 1 year. Method Patients were randomly assigne

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1798662732d7eae5509d46d25c14a81
https://pubmed.ncbi.nlm.nih.gov/26252780